Listen to the audio version of the article
It is a record budget, which for the first time exceeds 100 million in revenues, which will be submitted to the next Labomar Assembly, scheduled for 24 April 2024 in first call (7 May 2024 in second call if necessary).
The Board of Directors of Labomar, a leading company in the nutraceutical sector, active internationally and specialized in the research, development and contract production of food supplements, medical devices, foods for special medical purposes and cosmetics, has approved the draft financial statement financial year and the consolidated as of 31 December 2023, as well as the impact report for the year 2023 as a Benefit Company: the numbers show significantly growing results both in terms of turnover, which stands at 103.6 million euros ( +12.8 points compared to the 2022 financial year) and margins.
A result to which all the companies of the Group contribute, including the latest acquisitions: «For the first time in our history we have exceeded the threshold of one hundred million in revenues, almost doubling the turnover in just four years – comments the CEO and founder Walter Bertin -. A record, considering the complexities of the current economic and geopolitical context, as well as the changed dynamics of supply chains and the profound transformations that also affect the world of work. Looking to the future, 2024 marks a ‘new beginning’ for our Group. While remaining anchored to our usual values, such as the passion for well-being, the relationship with the customer, the drive for innovation, we are ready to face new challenges. Thanks to the partnership with a partner of primary standing such as Charterhouse and the strengthening of the management, we will return to evaluating possible further acquisitions as part of a complex growth plan both organically and externally”.
Growth
Labomar’s external growth path began in 2019 with the acquisition of Labomar Canada, and then continued in 2022 with the Welcare Group in Umbria and Labiotre in Tuscany. Each of these realities has added value to the Group, strengthening control of the supply chain in the nutraceutical sector. «Labomar demonstrated excellent organic growth in 2023, confirming its role as a leader and innovator in the nutraceutical sector. Furthermore, also thanks to the strengthening of the team we are now ready to seize important growth opportunities through acquisitions in Europe and North America, further consolidating Labomar’s leadership in the sector” adds Antonio Di Lorenzo, partner of Charterhouse, one of the oldest private equity firms operating in Europe which joined the Labomar team in 2023.
During the 2023 financial year, the integration between the companies began to show its results. The parent company Labomar Spa recorded a turnover of 79.4 million, equal to approximately 77% of total revenues. Compared to 2022, all Group companies achieved double-digit growth. At the same time, the number of employees also increased: as of 31 December 2023 there were 407, an increase of 13% compared to the previous year.